In preclinical models, it was demonstrated that recombinant human erythropoietin (rHuEPO) protected breast cancer cells against the anti-tumor effects of trastuzumab treatment through the activation of Src facilitated by JAK2 and PTEN inactivation. Here, SRC is linked to breast cancer.